Atherothrombosis is associated with the presence of a microinflammatory response, usually monitored by the use of C-reactive protein (CRP) measurements. In the Physician Health Study it was suggested that individuals who benefit most from the treatment are those who have enhanced concentrations of this biomarker. The possibility was suggested that one of the mechanisms of action of aspirin in thrombotic prevention is through its anti-inflammatory properties in terms of reducing the concentration of CRP. We conducted a regression analysis in a cohort of 3888 apparently healthy individuals and those with atherothrombotic risk factors and vascular events, 370 of whom were under the treatment of low doses (£ 325 mg/ day) of aspirin. The significant determinants of CRP concentrations included body mass index, oral contraceptives, hormonal replacement therapy, gender, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, physical activity, age, smoking status and the presence of diabetes mellitus but not the use of low dose of aspirin. We conclude that the use of low doses (£ 325 mg/day) of aspirin does not have a significant role in the modulation of CRP concentrations in apparently healthy individuals and those with atherothrombotic risk factors and vascular events. The anti-atherothrombotic activity of this drug is probably not mediated through a significant reduction of the concentration of this protein.
Introduction
It has been repeatedly shown that atherothrombosis is associated with the presence of a microinflammatory response [1] . C-reactive protein (CRP) is widely used for the detection and quantitation of this response [2] . In addition to being a biomarker, this protein might participate in the pathogenesis of the disease [3] . Therapeutic interventions have been shown to reduce the concentration of CRP [4, 5] , but the role of low-dose aspirin in this regard is not entirely clear.
We have presently analyzed the potential effect of low doses ( 325 mg/day) of aspirin on the concentrations of high-sensitivity CRP (hs-CRP) in a relatively large number of apparently healthy individuals and in those with atherothrombotic risk factors. The results are significant in that they show lack of a significant effect, suggesting that the protective effects of aspirin in atherothrombosis are probably not mediated through a significant reduction of CRP concentrations.
Methods

Study population
We have presently included individuals who participated in the Tel Aviv Medical Center Inflammation Survey [6] [7] [8] , a registered databank, Data Banks Registries, Ministry of Justice, State of Israel. This survey of apparently healthy individuals is currently taking place at our medical center and includes a relatively large cohort of individuals attending the Tel Aviv Sourasky Medical Center for a routine health examination. All the individuals included in the present survey gave their written consent according to the instructions of the Institutional Ethics Committee. Excluded were any individuals with an underlying inflammatory disease (arthritis, inflammatory bowel disease, etc.) as well as those with any infection or other inflammatory conditions, including infarction, surgery or angiography during the 6 months preceding study enrollment. We also excluded individuals treated with steroid or non-steroidal antiinflammatory medication, except for low doses of aspirin ( 325 mg/day). Finally in order to minimize the effect of extreme cases, we excluded 1.5% of the higher and lower values of hs-CRP.
Definitions of risk factors
Diabetes mellitus was defined as fasting blood glucose of at least 126 mg/dl or the use of insulin or oral hypoglycemic agents, hypertension as blood pressures of at least 140/90 mmHg or the use of anti-hypertensive medications, while hyperlipidemia was defined as cholesterol or triglyceride concentrations of at least 200 mg/dl or the use of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors or fibrates. As smokers we included both present smokers (at least 5 cigarettes/day) and past smokers (did not smoke for the last 30 days or more).
Laboratory measurements
The hs-CRP concentrations were measured using a Behring BN II Nephelometer (DADE Behring, Marburg, Germany) [9] .
Statistical analysis
The statistical analysis was performed once for all the cohort population and a second time separately for men and women. All data were summarized and displayed as the mean AE SD for the continuous variables (age, body mass index, all the inflammation markers, etc.), and as the number of patients plus the percentage in each group for categorical variables (smoking and other cardiovascular risk factors, medications, etc.). The cross-tabs and descriptive procedures were used to produce frequencies of categorical variables and the mean AE SD of continuous variables. The hs-CRP has a non-normal distribution, and thus we used a logarithmic transformation that converts it to a normal distribution for all statistical procedures such as regressions; all the results expressed for hs-CRP are a back-transformed geometrical mean and standard deviation. The one-sample Kolmogorov-Smirnov test was used to verify that the logarithmic transformation is normally distributed. For all categorical variables the chi-square phi and Cramer's V statistics were used for assessing the difference significance between those who take aspirin and the group without aspirin usage. Geometric means of CRP were adjusted for age, sex, smoking status, physical activity, alcohol consumption, body mass index, lipid profile including high-density lipoprotein, low-density lipoprotein and triglycerides, systolic and diastolic blood pressures, history of cardiovascular disease, cerebrovascular or peripheral arterial disease, history of diabetes mellitus, hyperlipidemia or hypertension, and the use of oral contraceptives, hormone replacement treatment, statins, fibrates, angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), using analysis of covariance, under a general linear model. We used the results of the same analysis to assess the main effect of the different components already mentioned on hs-CRP. In order to further assess which components contribute to the inflammation expressed as hs-CRP, we performed a linear regression using log(hs-CRP) as the dependent variable and all the aforementioned parameters as the covariates using the stepwise method. The level of significance used for all of the above analyses was two-tailed (P < 0.05). The SPSS statistical package was used to perform all statistical evaluation (SSPS Inc., Chicago, Illinois, USA).
Results
We have presently included a total of 3888 apparently healthy individuals and those with atherothrombotic risk factors at a mean AE SD age of 48.1 AE 12. There was no significant difference between aspirin users and non-users in regard to the concentration of hs-CRP (Table 3) , and this is true when the data were analyzed separately for men and women (Table 4) . Due to the possible opposite effect of a higher percentage of atherothrombotic risk factors that increases the concentration of hs-CRP, and the higher use of drugs that lowers the concentration of hs-CRP, such as statins and ACE inhibitors, in the aspirin users we performed a subanalysis without all patients taking any of these drugs (statins, fibrates, ACE inhibitors or ARBs), thus leaving just the higher percentage of atherothrombotic risk factors among aspirin users. This achieved the same results (data not shown).
Finally we performed a regression and show components that significantly affect the concentrations of hs-CRP (Table 5 ). Although some difference exists regarding the differential effects of these components among the genders (Table 6 ), the use of aspirin was not significant in any of them.
Discussion
The finding that the largest benefit of aspirin on the risk of a first myocardial infarction occurred in individuals with relatively high concentrations of CRP in the Physicians' Health Study [10] raised the possibility that one of the beneficial effects of this drug is through its influence on the concentrations of this protein. Such an influence might be dual, either a direct effect on the synthesis of the protein or an indirect one by reducing the overall intensity of the atherothrombotic process. The possibility that aspirin might have an effect on the concentrations of hs-CRP has already been subjected to several studies in the past [11] [12] [13] [14] [15] [16] [17] [18] [19] .
We herewith analyzed the data of a relatively large cohort of apparently healthy individuals and those with atherothrombotic risk factors, part of whom were taking medications that have a potential effect on the concentrations of CRP. The results are significant in that they show a lack of a significant effect on the concentrations of hs-CRP by aspirin use. The effect of oral contraceptives and hormonal replacement therapy was detected, through the regression analysis serving as an internal 'positive control' of our study.
Several studies in the past examined the potential role of aspirin in suppressing the concentration of CRP. Not all of the studies reached similar conclusions but they should not necessarily be considered as conflicting due to the fact that they refer to different study populations. For example, Feldman et al. [13] and Feng et al. [14] did not show a significant reduction of CRP levels by low-dose aspirin in healthy volunteers. However, this population, by definition, does not represent inflammation related to atheroma and, if elevated, subclinical infection or other smoldering inflammatory diseases might be the cause. On the other hand, Solheim et al. [12] or Ikonomidis et al. [11] found that aspirin reduced CRP in patients following acute myocardial infarction or with angiographically documented cardiovascular disease who present a high degree of inflammation within the vascular walls, and therefore are expected to benefit from the treatment. In this regard, it should be stressed that the present population includes subjects with a low atherothrombotic risk profile, a finding that might have relevance to the results.
We conclude that in our cohort of apparently healthy individuals and those with atherothrombotic risk factors and a history of vascular events, low doses ( 325 mg/ day) of aspirin were not found to have a dominant role in the expression of hs-CRP concentrations. Thus the protective effects of low doses of aspirin in atherothrombosis are probably not mediated through a significant reduction of this protein's concentrations.
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